Trial Profile
Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs ACE inhibitors; Candesartan cilexetil
- Indications Cardiovascular disorders; Diabetes mellitus; Hyperlipidaemia; Hypertension
- Focus Therapeutic Use
- Acronyms ARBACE
- Sponsors AstraZeneca
- 26 Sep 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 09 May 2011 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
- 09 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.